Monitoring
The first year following diagnosis, patients should be reviewed every 3 to 4 months, with restaging CT scan of chest, abdomen and pelvis performed every 4 months, plus blood tests including chromogranin A and urinary 5-hydroxyindoleacetic acid (5-HIAA).[74] If symptoms progress or deteriorate, patients may also undergo further Octreoscan®. From the second year onward, if tumor appears to be stable, then 6-monthly restaging scans, plus blood tests, and urinary 5-HIAA can be performed. Octreoscan® can be performed annually.[74]
Use of this content is subject to our disclaimer